{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"PRGO","limit":50},"count":50,"signals":[{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"t to Section 412(c) of the Code or Section 302(c) of ERISA of an application for a waiver of the minimum funding standard with respect to any Plan, the failure to make by its due date a required installment under Section 430(j) of the Code with respect to any Plan or the failure to make by its due date any required contribution to a Multiemployer Plan; (e) the incurrence by the Parent, a Restricted S","filed_date":"2026-03-23","accession":"0001585364-26-000028","full_text":"https://origin.rootz.global/static/filing/0001585364-26-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":36,"context":"........................................... 138 Section 3.05 Financial Statements ................................................................................................. 139 Section 3.06 No Material Adverse Effect ...................................................................................... 139 Section 3.07 Title to Properties; Possession Under Leases ..................................................","filed_date":"2026-03-23","accession":"0001585364-26-000028","full_text":"https://origin.rootz.global/static/filing/0001585364-26-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"25 equal to 2 times the actual AIP bonus awarded for 2024 performance, plus 10% (the RSU Grant). The RSU Grant was granted in addition to any annual award under the LTIP and will vest in 2 equal installments on the 1st and 2nd anniversary of the grant date.On February 26, 2025, Perrigo Company (a subsidiary of the Company) signed an Amended and Restated Employment Agreement with Mr. Lockwood-Taylor t","filed_date":"2026-03-20","accession":"0001585364-26-000024","full_text":"https://origin.rootz.global/static/filing/0001585364-26-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":53,"context":"and reward in relation to our overall business strategy and  are not designed in such a way to encourage executives and employees to take unnecessary risks that would  be reasonably likely to have a material adverse effect on Perrigo.  Benefits and Perquisites  Retirement Benefits for US Employees: We offer retirement benefit plans to provide financial security and to  facilitate employees saving for their retirement.","filed_date":"2026-03-20","accession":"0001585364-26-000024","full_text":"https://origin.rootz.global/static/filing/0001585364-26-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":47,"context":"mpensation | 38 | | | Ownership of Perrigo Ordinary Shares | 40 | | | Delinquent Section 16(a) Reports | 43 | | | Executive Compensation | 44 | | | Compensation Discussion and Analysis | 44 | | | Our Named Executive Officers for 2025 | 46 | | | 2025 Say-on-Pay Voting Results | 46 | | | Best Compensation Governance and Practices | 47 | | | | | iv | Perrigo Company | | | | | Page | | | What Guides Our Executive Compensati","filed_date":"2026-03-20","accession":"0001585364-26-000024","full_text":"https://origin.rootz.global/static/filing/0001585364-26-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":13,"context":"o execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including our ability to achieve the expected benefits from our ongoing restructuring programs described herein. Adverse results with respect to pending litigation could have a material adverse impact on our operating results, cash flows and liquidity, and could ultimately require the use of","filed_date":"2026-02-26","accession":"0001585364-26-000009","full_text":"https://origin.rootz.global/static/filing/0001585364-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":14,"context":"ets; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives; uncertainty regarding","filed_date":"2026-02-26","accession":"0001585364-26-000009","full_text":"https://origin.rootz.global/static/filing/0001585364-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":107,"context":"tives and investments, including our ability to achieve the expected benefits from our ongoing restructuring programs described herein. Adverse results with respect to pending litigation could have a material adverse impact on our operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corporate purp","filed_date":"2026-02-26","accession":"0001585364-26-000009","full_text":"https://origin.rootz.global/static/filing/0001585364-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"ent of $407.1million for CSCI, resulting in $881.3million of goodwill in this reporting unit after the impairment as of December31, 2025.Richard Bittner Business GoodwillOn March10, 2025, the Company signed a definitive agreement to sell the Richard Bittner Business to HBI Health & Beauty Innovations Limited. As a result, we determined an impairment indicator existed and prepared a quantitative goodwill impairment test. We de","filed_date":"2026-02-26","accession":"0001585364-26-000009","full_text":"https://origin.rootz.global/static/filing/0001585364-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"of the Company's estimated range of $140 million to $170 million. Reinvestments of savings of $35 million over the same period are within the Company's estimated range of $30 million to $40 million. Restructuring charges incurred by the Company over the same period in connection with Project Energize were approximately $138 million. As the program has substantively finalized, the Company anticipates less than $10 mil","filed_date":"2026-02-26","accession":"0001585364-26-000006","full_text":"https://origin.rootz.global/static/filing/0001585364-26-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":12,"context":"tivities | 18 | | | | | | | | | 12 | Indebtedness | 23 | | | | | 13 | Earnings per Share and Shareholders' Equity | 25 | | | | | 14 | Accumulated Other Comprehensive Income (Loss) | 25 | | | | | 15 | Restructuring Charges | 26 | | | | | 16 | Income Taxes | 27 | | | | | 17 | Commitments and Contingencies | 30 | | | | | 18 | Segment and Geographic Information | 35 | | | | | | | | | Item2. Managements Discussion and Anal","filed_date":"2025-11-05","accession":"0001585364-25-000156","full_text":"https://origin.rootz.global/static/filing/0001585364-25-000156.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"to be substantially incurred by the end of 2026. Since the beginning of the program, Project Energize has achieved gross annual savings of approximately $163 million with reinvestment of $32 million. Restructuring charges incurred by the Company over the same period in connection with Project Energize were $133 million.  Perrigo Third Quarter 2025 Results from Continuing Operations | | | | | | | | | | | | | | | | | |","filed_date":"2025-11-05","accession":"0001585364-25-000153","full_text":"https://origin.rootz.global/static/filing/0001585364-25-000153.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"tivities | 16 | | | | | | | | | 11 | Indebtedness | 21 | | | | | 12 | Earnings per Share and Shareholders' Equity | 23 | | | | | 13 | Accumulated Other Comprehensive Income (Loss) | 23 | | | | | 14 | Restructuring Charges | 24 | | | | | 15 | Income Taxes | 25 | | | | | 16 | Commitments and Contingencies | 27 | | | | | 17 | Segment and Geographic Information | 33 | | | | | 18 | Subsequent Events | 36 | | | | | Item2. M","filed_date":"2025-08-06","accession":"0001585364-25-000122","full_text":"https://origin.rootz.global/static/filing/0001585364-25-000122.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"ubstantially incurred by the end of 2026. Since the beginning of the program in 2024, Project Energize has achieved gross annual savings of approximately $159million with reinvestment of $27 million. Restructuring charges incurred by the Company over the same period in connection with Project Energize were $118 million.  3 Perrigo Second Quarter 2025 Results from Continuing Operations | | | | | | | | | | | | | | | | |","filed_date":"2025-08-06","accession":"0001585364-25-000120","full_text":"https://origin.rootz.global/static/filing/0001585364-25-000120.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"sk and reward in relation to our overall business strategy and are not designed in such a way to encourage executives and employees to take unnecessary risks that would be reasonably likely to have a material adverse effect on Perrigo.  Benefits and Perquisites  Retirement Benefits for US Employees: We offer retirement benefit plans to provide financial security and to facilitate employees saving for their retirement. W","filed_date":"2025-03-21","accession":"0000950170-25-042897","full_text":"https://origin.rootz.global/static/filing/0000950170-25-042897.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":48,"context":"errigo Ordinary Shares |  |  20 |  |  | |  Delinquent Section 16(a) Reports |  |  22 |  |  | |  Executive Compensation |  |  23 |  |  | |  Compensation Discussion and Analysis |  |  23 |  |  | |  Our Named Executive Officers for 2024 |  |  24 |  |  | |  2024 Say-on-Pay Voting Results |  |  24 |  |  | |  Best Compensation Governance and Practices |  |  25 |  |  | |  What Guides Our Executive Compensation Program |  |  26","filed_date":"2025-03-21","accession":"0000950170-25-042897","full_text":"https://origin.rootz.global/static/filing/0000950170-25-042897.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including the Company's ability to achieve the expected benefits from its ongoing restructuring programs described herein. Adverse results with respect to pending litigation could have a material adverse impact on the Company's operating results, cash flows and liquidity, and could ultimately require t","filed_date":"2025-02-28","accession":"0001585364-25-000014","full_text":"https://origin.rootz.global/static/filing/0001585364-25-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":103,"context":"investments, including the Company's ability to achieve the expected benefits from its ongoing restructuring programs described herein. Adverse results with respect to pending litigation could have a material adverse impact on the Company's operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corp","filed_date":"2025-02-28","accession":"0001585364-25-000014","full_text":"https://origin.rootz.global/static/filing/0001585364-25-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"nit was impaired by $90.0million and recorded the charge within our CSCI segment.82Perrigo Company plc - Item 8Note 9Orion Laboratories Hospital & Specialty Business GoodwillOn September 14, 2024, we signed a definitive agreement to sell the Hospital & Specialty Business within our CSCI segment to Genesis Capital. As a result, we determined an impairment indicator existed and prepared a quantitative goodwill impairment test.","filed_date":"2025-02-28","accession":"0001585364-25-000014","full_text":"https://origin.rootz.global/static/filing/0001585364-25-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":13,"context":"be substantially incurred by the end of 2026. Year-to-date, Project Energize has achieved gross savings of approximately $95 million while reinvesting $16 million into building critical capabilities. Restructuring charges incurred by the Company over the same period in connection with Project Energize were $91 million. Perrigo Third Quarter 2024 Results from Continuing Operations | | | | | | | | | | | | | | | | | | |","filed_date":"2024-11-06","accession":"0001585364-24-000138","full_text":"https://origin.rootz.global/static/filing/0001585364-24-000138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":13,"context":"be substantially incurred by the end of 2026. Year-to-date, Project Energize has achieved gross savings of approximately $95 million while reinvesting $16 million into building critical capabilities. Restructuring charges incurred by the Company over the same period in connection with Project Energize were $91 million. Perrigo Third Quarter 2024 Results from Continuing Operations | | | | | | | | | | | | | | | | | | |","filed_date":"2024-11-06","accession":"0001585364-24-000135","full_text":"https://origin.rootz.global/static/filing/0001585364-24-000135.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":13,"context":"addition to benefits from purposeful SKU prioritization actions in CSCA.  Reported operating loss of $27 million compared to operating income of $57 million in the prior year period, due primarily to restructuring charges related to Project Energize, an impairment recognized as part of the sale of HRA Pharma Rare Diseases business and unusual litigation costs. Adjusted operating income increased $2 million to $139 mil","filed_date":"2024-08-02","accession":"0001585364-24-000111","full_text":"https://origin.rootz.global/static/filing/0001585364-24-000111.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"sk and reward in relation to our overall business strategy and are not designed in such a way to encourage executives and employees to take unnecessary risks that would be reasonably likely to have a material adverse effect on Perrigo.  Benefits and Perquisites  Retirement Benefits. We offer retirement benefit plans to provide financial security and to facilitate employees saving for their retirement. We make annual con","filed_date":"2024-03-22","accession":"0000950170-24-035264","full_text":"https://origin.rootz.global/static/filing/0000950170-24-035264.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":40,"context":"f Perrigo Ordinary Shares |  |  18 |  |  | |  Delinquent Section 16(a) Reports |  |  20 |  |  | |  Executive Compensation |  |  21 |  |  | |  Compensation Discussion and Analysis |  |  |  |  | |  Our Named Executive Officers for 2023 |  |  22 |  |  | |  2023 Say-on-Pay Voting Results |  |  23 |  |  | |  Best Compensation Governance and Practices |  |  25 |  |  | |  What Guides Our Executive Compensation Program |  |  26","filed_date":"2024-03-22","accession":"0000950170-24-035264","full_text":"https://origin.rootz.global/static/filing/0000950170-24-035264.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":93,"context":"d benefits from its ongoing restructuring programs described herein. Adverse results with respect to the Companys appeal of any material outstanding tax assessments or pending litigation could have a material adverse impact on the Company's operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corp","filed_date":"2024-02-27","accession":"0001585364-24-000009","full_text":"https://origin.rootz.global/static/filing/0001585364-24-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":10,"context":"RMATION ABOUT OUR EXECUTIVE OFFICERS Our executive officers and their ages and positions as of February23, 2024 were: | | | Title and Business Experience | Age | | | Svend Andersen | Mr. Andersen was named Executive Vice President and President, Consumer Self-Care International in February 2017. Prior to joining Perrigo in May 2016, Mr. Andersen served as Executive Vice President - Europe for LEO-Pharma from December 2015 to May 2016. | 62","filed_date":"2024-02-27","accession":"0001585364-24-000009","full_text":"https://origin.rootz.global/static/filing/0001585364-24-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"t to Section 412(c) of the Code or Section 302(c) of ERISA of an application for a waiver of the minimum funding standard with respect to any Plan, the failure to make by its due date a required installment under Section 430(j) of the Code with respect to any Plan or the failure to make by its due date any required contribution to a Multiemployer Plan; (e) the incurrence by the Parent, a Restricted S","filed_date":"2023-12-15","accession":"0001193125-23-296684","full_text":"https://origin.rootz.global/static/filing/0001193125-23-296684.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"Loan Parties set forth in the Loan Documents are true and correct in all material respects (except that any representation or warranty which is already qualified as to materiality or by reference to Material Adverse Effect is true and correct in all respects) on and as of such date, with the same effect as if made on and as of such date (other than those representations and warranties that by their terms expressly rela","filed_date":"2023-12-15","accession":"0001193125-23-296684","full_text":"https://origin.rootz.global/static/filing/0001193125-23-296684.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"sk and reward in relation to our overall business strategy and are not designed in such a way to encourage executives and employees to take unnecessary risks that would be reasonably likely to have a material adverse effect on Perrigo.  Benefits and Perquisites  Retirement Benefits. We offer retirement benefit plans to provide financial security and to facilitate employees saving for their retirement. We make annual con","filed_date":"2023-03-24","accession":"0001193125-23-078876","full_text":"https://origin.rootz.global/static/filing/0001193125-23-078876.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":41,"context":"| | |  Delinquent Section16(a) Reports |  |  |  20 |  | | |  |  | | |  Executive Compensation |  |  |  21 |  | | |  |  | | |  Compensation Discussion and Analysis |  |  |  21 |  | | |  |  | | |  Our Named Executive Officers for 2022 |  |  |  23 |  | | |  |  | | |  2022 Say-on-Pay Voting Results |  |  |  23 |  | | |  |  | | |  Best Compensation Governance and Practices |  |  |  25 |  | | |  |  | | |  What Guides Our Exe","filed_date":"2023-03-24","accession":"0001193125-23-078876","full_text":"https://origin.rootz.global/static/filing/0001193125-23-078876.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":53,"context":"e the expected benefits from its Supply Chain Reinvention Program. An adverse result with respect to the Companys appeal of any material outstanding tax assessments or pending litigation could have a material adverse impact on the Company's operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay such assessments, damages from third-party claims, and related interest a","filed_date":"2023-02-28","accession":"0001585364-23-000006","full_text":"https://origin.rootz.global/static/filing/0001585364-23-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"adversely impacted.  Management transition creates uncertainties, and any difficulties we experience in managing such transitions may negatively impact our business. During 2022, Eduardo Bezerra was named Executive Vice President and Chief Financial Officer. Additionally, Kyle Hanson joined the Company as Executive Vice President, General Counsel and Corporate Secretary and Alison Ives was promoted to Executive Vice President and Chief","filed_date":"2023-02-28","accession":"0001585364-23-000006","full_text":"https://origin.rootz.global/static/filing/0001585364-23-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":45,"context":"lion acquisition of HRA Pharma. Significantly reduced uncertainty by favorably settling the Irish tax dispute, removing a potential exposure of 1.6 billion.  Other important accomplishments include:  Announced definitive agreement to sell Mexico and Brazil based OTC business as part of margin improvement program and cost savings initiative. Led the reduction of packaging materials by 164M tons, which far exceeded expectations.","filed_date":"2022-03-24","accession":"0001193125-22-083412","full_text":"https://origin.rootz.global/static/filing/0001193125-22-083412.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"r net sales may be negatively impacted and we may lose market share. We operate in highly regulated industries, and any inability to timely meet current or future regulatory requirements could have a material adverse effect on our business and operating results. Limitations on reimbursement, continuing healthcare reforms, and changes to reimbursement methods in the United States and other countries may have an adverse e","filed_date":"2022-03-01","accession":"0001585364-22-000011","full_text":"https://origin.rootz.global/static/filing/0001585364-22-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":27,"context":"er 31, 2019  The $408.3million decrease in cash used in investing cash flow was due primarily to: $579.2 million decrease in cash used due to the absence of the payment made in the prior year for the acquisition of Ranir for $747.7million, partially offset by the cash paid for the acquisitions of Dr. Fresh for $106.2million and Eastern European dermatology brands for $62.3 million (refer to [Item 8. Note 3](#i94ff310470294","filed_date":"2022-03-01","accession":"0001585364-22-000011","full_text":"https://origin.rootz.global/static/filing/0001585364-22-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"Loan Parties set forth in the Loan Documents are true and correct in all material respects (except that any representation or warranty which is already qualified as to materiality or by reference to Material Adverse Effect is true and correct in all respects) on and as of such date, with the same effect as if made on and as of such date (other than those representations and warranties that by their terms expressly rela","filed_date":"2021-12-09","accession":"0001193125-21-352158","full_text":"https://origin.rootz.global/static/filing/0001193125-21-352158.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":12,"context":"have been included and include our accounts and the accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. On March 1, 2021, we announced a definitive agreement to sell our generic RX Pharmaceuticals business (\"RX business\") to Altaris Capital Partners, LLC (\"Altaris\"). On July6, 2021, we completed the sale of the RX business. The financial results of our RX","filed_date":"2021-11-12","accession":"0001585364-21-000112","full_text":"https://origin.rootz.global/static/filing/0001585364-21-000112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":38,"context":"of the date of the AGM. | | |  |  |  |  |  | | |  |  |  |  |  ii | | [Table of Contents](#toc) |  |  |  | | |  Proxy Summary |  |  | | **Executive Transition/Succession Planning** Richard Sorota was appointed Executive Vice President, President, Consumer Health Care Americas in March 2020, following the announced retirement of Jeffrey R. Needham.  **2020 Performance Update1** In fiscal year 2020, management and the Board of Direc","filed_date":"2021-04-01","accession":"0001193125-21-103904","full_text":"https://origin.rootz.global/static/filing/0001193125-21-103904.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"f Seller Manufacturing and Supply Agreement | | |  Exhibit E-3 |  |  Form of ORx Distribution Agreement | | |  Exhibit F |  |  Form of IP Assignment Agreements | | |  |  | | |  Annex A |  |  Internal Restructuring Plan | | -iv-  STOCK AND ASSET PURCHASE AGREEMENT  This STOCK AND ASSET PURCHASE AGREEMENT, dated as of March 1, 2021 (this Agreement), is by and between PERRIGO COMPANY PLC, an Irish public limited compa","filed_date":"2021-03-02","accession":"0001193125-21-065587","full_text":"https://origin.rootz.global/static/filing/0001193125-21-065587.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"ird party any right or license to any Business Intellectual Property, including, in the case of clauses (a) and (b), license agreements, settlement agreements and covenants not to sue.  -3-  Business Material Adverse Effect means any event, occurrence, change or development or effect that, individually or in the aggregate, has had, or would reasonably be expected to have, a material adverse effect on the business, finan","filed_date":"2021-03-02","accession":"0001193125-21-065587","full_text":"https://origin.rootz.global/static/filing/0001193125-21-065587.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":20,"context":"ges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company's appeal of the Notice of Assessment (\"NoA\") issued by the Irish Office of the Revenue Commissioners (Irish","filed_date":"2021-03-01","accession":"0001585364-21-000012","full_text":"https://origin.rootz.global/static/filing/0001585364-21-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"comply with the reporting and payment obligations under the Medicaid rebate program or other governmental purchasing and rebate programs, we could be subject to fines or penalties, which could have a material adverse effect on our financial condition and results of operations in [Item 1A. Risk Factors - Operational Risks](#i1604744feebe4c0e8e79a1b5c8b373a6_58). 340B Program Agreement The 340B drug pricing program requir","filed_date":"2021-03-01","accession":"0001585364-21-000012","full_text":"https://origin.rootz.global/static/filing/0001585364-21-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"ber31, 2020 vs. December31, 2019  The $408.3million decrease in cash used in investing cash flow was due primarily to: $579.2 million decrease in cash used due to the absence of the cash paid for the acquisition of Ranir for $747.7million, partially offset by the cash paid for the acquisitions of Dr. Fresh for $106.2million and Eastern European dermatology brands for $62.3 million (refer to [Item 8. Note 3](#i1604744feebe4","filed_date":"2021-03-01","accession":"0001585364-21-000012","full_text":"https://origin.rootz.global/static/filing/0001585364-21-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"and, where applicable, with companies in similar industries and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe obscure underlying business operational trends. The intangibl","filed_date":"2021-03-01","accession":"0001585364-21-000009","full_text":"https://origin.rootz.global/static/filing/0001585364-21-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"rability between periods and companies in similar industries and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe obscure underlying business operational trends. The intangibl","filed_date":"2020-11-04","accession":"0001585364-20-000094","full_text":"https://origin.rootz.global/static/filing/0001585364-20-000094.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":101,"context":"L. Mann was appointed to the Board in 2019. | | |  |  |  |  Average tenure: approximately 2.9 years as of the date of the AGM. | | **Executive Transition/Succession Planning** Raymond P. Silcock was appointed Executive Vice President and Chief Financial Officer in March 2019, following the announced separation of Ronald L. Winowiecki, who had served in that role since April 2017.  **2019 Performance Update1** In fiscal year 2019, the Compa","filed_date":"2020-03-27","accession":"0001193125-20-087775","full_text":"https://origin.rootz.global/static/filing/0001193125-20-087775.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":25,"context":"ion; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company's appeal of the Notice of Assessment (\"NoA\") issued by the Irish Office of the Revenue Commissioners (Irish","filed_date":"2020-02-27","accession":"0001585364-20-000013","full_text":"https://origin.rootz.global/static/filing/0001585364-20-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":44,"context":"ally, or through treaty negotiation. While we believe our position to be correct, there can be no assurance of an ultimate favorable outcome, and if the matter is resolved unfavorably it could have a material adverse impact on our liquidity and capital resources. Irish Tax Appeals Commission Notice of Amended Assessment On October 30, 2018, we received an audit finding letter from the Irish Office of the Revenue Commiss","filed_date":"2020-02-27","accession":"0001585364-20-000013","full_text":"https://origin.rootz.global/static/filing/0001585364-20-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"believe that new products and products switching from Rx to OTC status (as described above) will continue to drive growth within the segment. Recent Developments  | | | | | | On February20, 2020, we entered into a definitive agreement to acquire the oral care assets of High Ridge Brands for cash of $113.0 million. The transaction is expected to close in the first quarter of 2020 subject to bankruptcy court approval in connection w","filed_date":"2020-02-27","accession":"0001585364-20-000013","full_text":"https://origin.rootz.global/static/filing/0001585364-20-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRGO","company":"PERRIGO Co plc","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"ility between periods and companies in similar industries  9 and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe obscure underlying business operational trends. The non-GAAP","filed_date":"2020-02-27","accession":"0001585364-20-000010","full_text":"https://origin.rootz.global/static/filing/0001585364-20-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"59e1ed0d692e0d0bd498b61876fa43989a4fc268542fa3802cab0ff1664da4ad","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"427bf1df141e85a5ced13fd7c0f34ce4e905a891b2c154e8b636c45e3071a737","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":163,"hourly_limit":500,"remaining":337,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}